Endometrial Cancer
If it’s your first time on this website, please read the disclaimer section.
May 25 – Jun 01, 2026
Four-year survival outcomes with dostarlimab plus chemotherapy in mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer in the RUBY trial.
GYNECOL ONCOL · Q1 JOURNAL - RANK #11/140
This is a prospective, randomized, double-blind, placebo-controlled Phase 3 clinical trial (RUBY, NCT03981796) evaluating dostarlimab plus carboplatin-paclitaxel (CP) versus placebo plus CP in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer. With a median follow-up of 55.6 months, the study reports descriptive analyses of overall survival (OS) and progression-free survival (PFS), plus post-hoc conditional survival and mixture cure model (MCM) analyses to estimate curative potential. Key findings include a 66% reduction in risk of death, median PFS and OS not reached, and a 54% (95% CI 35%-72%) cure rate estimated by MCM at 4 years with dostarlimab plus CP. The authors conclude that dostarlimab plus CP demonstrates sustained remission and long-term survival benefit, suggesting potential for curative intent in this patient population.
10.1016/j.ygyno.2026.05.008
Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249.
GYNECOL ONCOL · Q1 JOURNAL - RANK #11/140
The study aimed to determine whether mismatch repair (MMR) and p53 expression predict recurrence-free survival (RFS) and overall survival (OS) in early-stage endometrial cancer (EC) patients treated with vaginal cuff brachytherapy plus chemotherapy (VCB/C) versus pelvic radiation therapy (RT). In the GOG-0249 trial, 601 patients with high-intermediate risk (HIR) early-stage EC were randomized to VCB/C or pelvic RT, with molecular subgroups analyzed by immunohistochemistry. Five-year RFS and OS were worse in patients with p53abn cancers (58.7% RFS, HR=4.0; 70.7% OS, HR=9.4) and dMMR cancers (74.4% RFS, HR=1.8; 84.3% OS, HR=3.0) compared to p53wt (83.4% RFS, 95.3% OS). Molecular classification was prognostic for survival, but treatment outcomes did not differ by molecular subgroup, highlighting the need for novel therapies for high-risk patients.
10.1016/j.ygyno.2026.05.013
May 11 – May 18, 2026
Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses.
J GYNECOL ONCOL · Q1 JOURNAL - RANK #14/140
This study assessed the antitumor activity, safety, and exploratory biomarker analyses of trastuzumab deruxtecan (T-DXd) in HER2-expressing gynecologic cancers through the DESTINY-PanTumor02 phase 2 clinical trial. Pretreated patients with locally advanced, metastatic, or unresectable HER2-expressing gynecologic cancers received 5.4 mg/kg of T-DXd, and outcomes such as confirmed objective response rates (ORR), safety, progression-free survival, and overall survival were measured. Investigator-assessed ORRs were 57.5% (endometrial), 50.0% (cervical), and 45.0% (ovarian) cancer cohorts, with safety data revealing interstitial lung disease/pneumonitis occurrence in 10.8% of patients. The findings demonstrate clinically meaningful efficacy of T-DXd and support its use in pretreated HER2-expressing gynecologic cancers, with a manageable safety profile.
10.3802/jgo.2026.37.e65
A Phase II Evaluation of the Efficacy and Safety of Sacituzumab Govitecan in Patients with Recurrent Uterine Cancer.
CLIN CANCER RES · Q1 JOURNAL - RANK #29/326TOP-TIER
This phase II open-label clinical trial evaluated the efficacy and safety of sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate, in patients with recurrent uterine cancer who had progressed after at least one prior chemotherapy. The trial enrolled 50 patients in two stages with a median follow-up of 11 months, reporting an objective response rate (ORR) of 28% (95% CI, 16%-42%) and a clinical benefit rate (CBR) of 52%. Median progression-free survival was 5.5 months (95% CI, 3.7-7.4), and median overall survival was 17.5 months (95% CI, 10.4-22.2). SG showed promising efficacy in a heavily pretreated population with aggressive cancers, though Grade 3-4 toxicities occurred in 88% of patients, aligning with the known safety profile.
10.1158/1078-0432.CCR-26-0144
Prognostic value of the SENTIREC-endo algorithm integrating sentinel lymph node and FDG-PET/CT in staging high-risk endometrial cancer.
EJSO-EUR J SURG ONC · Q1 JOURNAL - RANK #54/312
This prospective national non-randomized cohort study (2017–2023) evaluated the SENTIREC-endo algorithm, which integrates sentinel lymph node mapping and FDG-PET/CT for targeted lymph node dissection, in women with high-risk endometrial cancer. Participants underwent the SENTIREC-endo algorithm followed by systematic lymph node dissection, allowing within-cohort comparison of time to progression and mortality, as well as assessment of lymphovascular space invasion (LVSI) as a prognostic variable. The SENTIREC-endo algorithm demonstrated significant discrimination in survival outcomes (p = 0.001), with performance paralleling systematic lymphadenectomy; LVSI had a strong prognostic association (p = 0.0004) but low sensitivity for nodal metastasis (38%, 95% CI 24–54%). The results support the continued use of surgical lymph node dissection for staging in high-risk endometrial cancer.
10.1016/j.ejso.2026.111878
Apr 20 – Apr 27, 2026
Safety and Efficacy of Lucitanib Plus Toripalimab in Advanced Solid Tumors Refractory to Standard Therapies: An Open-Label, Multicenter, Phase II Study.
MEDCOMM · Q1 JOURNAL - RANK #14/195TOP-TIER
This open-label, multicenter, single-arm Phase II study examined lucitanib combined with toripalimab in 131 patients with advanced solid tumors refractory to standard therapies. Patients were categorized into four cohorts based on tumor type, and the primary outcome, objective response rate (ORR), ranged from 13.5% to 45.8% across cohorts. Secondary outcomes included progression-free survival (PFS), which was highest in the NPC (PD-1-naïve) cohort with a median of 6.5 months (95% CI, 4.0-NE). The treatment demonstrated promising antitumor activity with manageable toxicity, including hypertension (37.4%), proteinuria (10.7%), and thrombocytopenia (10.7%), warranting further randomized investigations in specific tumor subtypes like NPC and EC.
10.1002/mco2.70672
Apr 13 – Apr 20, 2026
Efficacy and safety of cadonilimab combined with chemotherapy as first-line treatment for primary advanced or recurrent endometrial cancer: An interim analysis of a prospective, single-arm, open-label phase II trial.
GYNECOL ONCOL · Q1 JOURNAL - RANK #11/140
This investigator-initiated, multicenter, open-label, single-arm phase II trial prospectively evaluated cadonilimab, a PD-1/CTLA-4 bispecific antibody, combined with platinum-based chemotherapy as first-line therapy in women (18–75 y) with FIGO stage III/IV or recurrent endometrial cancer. Twenty-seven efficacy-evaluable patients received cadonilimab 10 mg/kg every three weeks plus chemotherapy, then cadonilimab maintenance; outcomes were measured by RECIST v1.1 with primary endpoint objective response rate (ORR) and secondary endpoints including DCR, DoR, PFS, OS, and safety, alongside exploratory biomarker subgroup analyses. Interim results showed ORR 74.1 % (95 % CI 55.6–87.3 %) with one complete and 19 partial responses, DCR 96.3 %, median DoR 17.8 months, median PFS 10.5 months (95 % CI 8.2–NE), and 12-month OS 90.2 %; grade ≥3 treatment-related adverse events occurred in 18.5 %, with no treatment-related deaths. The authors conclude that cadonilimab plus chemotherapy demonstrates clinically meaningful antitumor activity and manageable safety as first-line therapy for advanced or recurrent endometrial cancer, warranting further study particularly in molecularly defined subgroups.
10.1016/j.ygyno.2026.03.014